- Exchange: EN Brussels
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Biotech
ThromboGenics NV+ Add to Watchlist
THR:BB5.6490 EUR 0.1220 2.11%
As of 11:35:00 ET on 05/22/2015.
Company Profile for ThromboGenics NV (THR)
ThromboGenics NV is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company is focused on developing medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system.
Key Executives for ThromboGenics NV (THR)
|Patrik De HaesCEO/Executive Director||Dominique VanfleterenChief Financial Officer|
|Claude SanderChief Legal Officer||Laurence RaemdonckHead:Human Resources|
|Aniz GirachHead:Clinical Ophthalmology||Andy De DeeneHead:Clinical & Product Dev|
|David PearsonHead:Corporate Dev||Edward F KessigHead:US Commercial Ops|
|Jean FeyenHead:Preclinical Research||Wouter PiepersGlobal Head:Corporate Communications|